Irvin pharmaceutical distributor is negotiating with Roche about the production of risdiplam (TN Evrysdi) in Russia, Medusa reports with reference to the source.
This medicine is used for the treatment of spinal muscular atrophy (SMA), a severe genetic disease. The administration of the drug has to continue for life; in Russia, the retail price of one bottle is about 800,000 rubles; a child needs about 31 bottles a year, which will cost 24 million rubles.
A Roche’s representative said that the company was considering possible localization of Evrysdi, but did not disclose any details, the publication notes. At the same time, Roche states that Irvin-2, Irvin’s related structure, a company with the same owners and the same chief executive, is the a strategic partner for risdiplam production in Russia.
In July, it was reported that the Russian regions will receive Roche’s Evrysdi (risdiplam) for children with SMA who are supported by the Circle of Kindness Foundation, for a total cost of 129.9 million rubles.